Rabies-based vaccine induces potent immune responses against Nipah virus

Vaccine constructs. a Schematic representation of recombinant rabies virus (attenuated SAD B19 vaccine strain) genome expressing codon-optimized Nipah virus glycoprotein gene (Bangladesh strain) in between the nucleoprotein (N) and phosphoprotein (P) genes of rabies. An asterisk indicates the Arg→Glu mutation in amino acid position 333 of RABV G that attenuates neurovirulence. Parental vector with no foreign gene insertion, used as a negative control in immunogenicity and pathogenicity studies, is also depicted. b Confocal microscopy image of VERO E6 cells that were ether mock infected or infected at an MOI of 0.01 for 48？h with live NIPARAB or BNSP333 before fixing and dual staining with a human monoclonal antibody directed against RABV G (green) and either polyclonal sera from mice immunized with INAC NIPARAB (pooled sera 45 days post-infection (dpi) from mice receiving 2 doses of 10ug each) or live rVSV-HeV-G (pooled sera 57 dpi from mice receiving one i.n. dose of 1E5 pfu) (red). Scale bars represent 24？μ